TC
BIO icon

Trilogy Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Trilogy Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2
Closed -$1K – 180
2018
Q3 		$1K Hold
2
– – ﹤0.01% 538
2018
Q2 		$1K Buy
+2
New +$552 ﹤0.01% 501

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Trilogy Capital's BIO Position: Q4 2018 in Review

Trilogy Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2018, closing a stake of 2 shares — an estimated $1K sold.

Trilogy Capital first reported a position in BIO in Q2 2018 and held it in 2 quarters. The position peaked at $1K in Q3 2018. 328 funds tracked by Wall St. Rank hold BIO as of Q4 2018.

  • Trilogy Capital reported no remaining Bio-Rad Laboratories Class A position as of Q4 2018 after selling out during the quarter.
  • Trilogy Capital sold 2 Bio-Rad Laboratories Class A shares in Q4 2018, an estimated $1K.
  • Trilogy Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2018 and held it in 2 quarters.
  • Trilogy Capital's Bio-Rad Laboratories Class A position peaked at $1K in Q3 2018.
  • 328 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.